Table 1.
Baseline characteristics
| Overall population (N=1288) | Patients taking infliximab (n=871) | Patients taking vedolizumab (n=417) | p value | ||
|---|---|---|---|---|---|
| Vaccination schedule | .. | .. | .. | >0·99 | |
| Homologous | 545 (42·3%) | 369 (42·4%) | 176 (42·2%) | .. | |
| Heterologous | 740 (57·5%) | 501 (57·5%) | 239 (57·3%) | .. | |
| Missing | 3 (0·2%) | 1 (0·1%) | 2 (0·5%) | .. | |
| Age, years | 46·1 (33·6–58·2) | 43·6 (32·5–55·5) | 51·30 (37·20–63·30) | <0·0001 | |
| Sex | .. | .. | .. | 0·42 | |
| Female | 610 (47·4%) | 401 (46·0%) | 209 (50·1%) | .. | |
| Male | 671 (52·1%) | 465 (53·4%) | 206 (49·4%) | .. | |
| Other | 2 (0·2%) | 1 (0·1%) | 1 (0·2%) | .. | |
| Missing | 5 (0·4%) | 4 (0·5%) | 1 (0·2%) | ||
| BMI, kg/m2 | 25·9 (22·9–30·2) | 25·9 (22·8–30·4) | 25·92 (23·09–29·52) | 0·96 | |
| Race | .. | .. | .. | 0·25 | |
| Asian | 46 (3·6%) | 24 (2·8%) | 22 (5·3%) | .. | |
| Black | 7 (0·6%) | 5 (0·6%) | 2 (0·5%) | .. | |
| Mixed | 15 (1·2%) | 10 (1·2%) | 5 (1·2%) | .. | |
| Other | 6 (0·5%) | 4 (0·5%) | 2 (0·5%) | .. | |
| White | 1209 (93·9%) | 824 (94·6%) | 385 (92·3%) | .. | |
| Missing | 5 (0·4%) | 4 (0·5%) | 1 (0·2%) | .. | |
| Smoking | .. | .. | .. | 0·14 | |
| Never | 726 (56·3%) | 499 (57·3%) | 227 (54·4%) | .. | |
| Not currently | 450 (34·9%) | 290 (33·3%) | 160 (38·4%) | .. | |
| Current | 104 (8·1%) | 76 (8·7%) | 28 (6·7%) | .. | |
| Missing | 8 (0·6%) | 6 (0·7%) | 2 (0·5%) | .. | |
| Diagnosis | .. | .. | .. | <0·0001 | |
| Crohn's disease | 767 (59·6%) | 614 (70·5%) | 153 (36·7%) | .. | |
| Ulcerative colitis or unclassified IBD | 521 (40·5%) | 257 (29·5%) | 264 (63·3%) | .. | |
| Duration of IBD, years | 11 (6–20) | 11 (5–19) | 12 (7–21) | 0·00050 | |
| PRO2 active disease | 264 (20·5%) | 178 (20·4%) | 86 (20·6%) | >0·99 | |
| Immunomodulators | 627 (48·7%) | 537 (61·7%) | 90 (21·6%) | <0·0001 | |
| Steroids | 64 (5·0%) | 31 (3·6%) | 33 (7·9%) | <0·0001 | |
| Mesalazine | 330 (25·6%) | 185 (21·2%) | 145 (34·8%) | <0·0001 | |
| Heart disease | 53 (4·1%) | 24 (2·8%) | 29 (7·0%) | <0·0001 | |
| Lung disease | 167 (13·0%) | 104 (12·0%) | 63 (15·2%) | 0·12 | |
| Kidney disease | 19 (1·5%) | 11 (1·3%) | 8 (1·9%) | 0·36 | |
| Cancer | 7 (0·5%) | 2 (0·2%) | 5 (1·2%) | 0·040 | |
| Any diabetes | 73 (5·7%) | 40 (4·6%) | 33 (7·9%) | 0·016 | |
| Timing intervals, days | .. | .. | .. | .. | |
| Between third vaccine dose and blood sampling | 40 (26–53) | 40 (26–53) | 39 (26–53) | 0·89 | |
| Between dose 1 and 2 | 77 (70–78) | 77 (70–78) | 76 (70–78) | 0·51 | |
| Between dose 2 and 3 | 189 (173–201) | 188 (171–200) | 191 (179–202) | 0·00050 | |
Data are median (IQR) or n (%). p values were calculated using the Mann-Whitney U test or Fisher's exact test, comparing infliximab vs vedolizumab recipients. Homologous schedule comprises three doses of mRNA vaccine, heterologous schedule comprises two doses of adenovirus vector vaccine plus one dose of mRNA vaccine. IBD=inflammatory bowel disease. PRO2=patient reported outcomes